Cwestiwn ysgrifenedig WQ98449
- Gofynnwyd gan
- Rhys ab OwenAnnibynnol
- I'w ateb gan
- Cabinet Secretary for Health and Social Care
- Cyflwynwyd
- Dyddiad ateb
- Atebwyd
- Amser i'w ateb
- 5 diwrnod
Cwestiwn
Mae'r cwestiwn a'r ateb yn Saesneg gan nad oes fersiwn Gymraeg ar gael.
Is the Cabinet Secretary aware of cases of morbidly obese patients with a high BMI requiring intramuscular depot injections being regarded as treatment resistant?
Ateb
Atebwyd gan Cabinet Secretary for Health and Social Care
The successful administration of long-acting injectable medicines can be more challenging in people with a particularly high body mass index. Healthcare professionals administering these medicines should follow national guidelines on administration of oil-based depot and other long-acting intramuscular injections and any product specific instructions included in the manufacturer’s product information.
Some long-acting injectable medicines are supplied with specific needles as part of their marketing authorisation, and which will have been subject to rigorous licensing trials which included obese participants. In these cases, the manufacturer’s recommended needles should be used.
Treatment decisions including those regarding the appropriate selection of treatment, method of administration and assessment of effectiveness are matters for clinicians providing patients’ care.